# A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

> **NCT03206073** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 34 (actual)

## Conditions studied

- Colorectal Cancer
- Colorectal Carcinoma
- Colorectal Adenocarcinoma
- Refractory Cancer
- Colorectal Neoplasms

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab
- **BIOLOGICAL:** Pexa-Vec
- **BIOLOGICAL:** Pexa-Vec

## Key facts

- **NCT ID:** NCT03206073
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-07
- **Primary completion:** 2020-09-24
- **Final completion:** 2022-06-30
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2023-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03206073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03206073, "A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03206073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*